ALKS Quote, Financials, Valuation and Earnings

Avadel Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -10%. Alkermes PLC's return on equity of 25.91% beat Avadel Pharmaceuticals PLC's return on equity of -63.43%.

Alkermes PLC has a consensus price target of $39.57, signalling upside risk potential of 30.34%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.50 which suggests that it could grow by 102.55%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.512, which suggesting that the stock is 48.82% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.397, suggesting its more volatile than the S&P 500 by 39.743%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $50.4M. Alkermes PLC's net income of $22.5M is higher than Avadel Pharmaceuticals PLC's net income of -$5M. Notably, Alkermes PLC's price-to-earnings ratio is 14.53x while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.37x versus 4.86x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of 17.56%. Alkermes PLC's return on equity of 25.91% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Alkermes PLC has a consensus price target of $39.57, signalling upside risk potential of 30.34%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $190.28 which suggests that it could grow by 71.16%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.512, which suggesting that the stock is 48.82% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.382, suggesting its less volatile than the S&P 500 by 61.836%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $22.5M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Alkermes PLC's price-to-earnings ratio is 14.53x while Jazz Pharmaceuticals PLC's PE ratio is 12.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.37x versus 1.75x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of 15.61%. Alkermes PLC's return on equity of 25.91% beat Medtronic PLC's return on equity of 8.56%.

Alkermes PLC has a consensus price target of $39.57, signalling upside risk potential of 30.34%. On the other hand Medtronic PLC has an analysts' consensus of $97.10 which suggests that it could grow by 17.95%. Given that Alkermes PLC has higher upside potential than Medtronic PLC, analysts believe Alkermes PLC is more attractive than Medtronic PLC.

Alkermes PLC has a beta of 0.512, which suggesting that the stock is 48.82% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.811, suggesting its less volatile than the S&P 500 by 18.855%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.4% to investors and pays a quarterly dividend of $0.70 per share. Alkermes PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Medtronic PLC quarterly revenues of $8.3B. Alkermes PLC's net income of $22.5M is lower than Medtronic PLC's net income of $1.3B. Notably, Alkermes PLC's price-to-earnings ratio is 14.53x while Medtronic PLC's PE ratio is 25.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.37x versus 3.22x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of 7.33% compared to Alkermes PLC's net margin of -3.91%. Alkermes PLC's return on equity of 25.91% beat Perrigo Co PLC's return on equity of -3.76%.

Alkermes PLC has a consensus price target of $39.57, signalling upside risk potential of 30.34%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 40.2%. Given that Perrigo Co PLC has higher upside potential than Alkermes PLC, analysts believe Perrigo Co PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.512, which suggesting that the stock is 48.82% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.199%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.53% to investors and pays a quarterly dividend of $0.29 per share. Alkermes PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

Alkermes PLC quarterly revenues are $306.5M, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $22.5M is higher than Perrigo Co PLC's net income of -$44.5M. Notably, Alkermes PLC's price-to-earnings ratio is 14.53x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.37x versus 0.78x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.